Engineered immune cells with nanomaterials to improve adoptive cell therapy

Cited 0 time in webofscience Cited 0 time in scopus
  • Hit : 17
  • Download : 0
Cell-based cancer immunotherapy is mainly performed to re-stimulate or boost the anti-tumor immunity by leveraging the anti-tumoral functions of infused cells. Although conventional adoptive cell therapy with T cells and DC vaccines had potentiated the use of ex vivo engineered cells for cancer immunotherapy, these approaches had a low success rate and some off-target side effects. Recent developments on this intervention are adopting nanoengineering to overcome limitations imposed by the environment the therapeutic cells would be in and the natural characteristics of the cells; thus, enhancing the efficacy of therapies. For this purpose, T cells, NK cells, DCs, and macrophages are engineered to either maintain anti-tumoral phenotypes, target tumor efficiently, or improve the innate functionalities and viability.
Publisher
SPRINGERNATURE
Issue Date
2021-07
Language
English
Article Type
Review
Citation

BIOMEDICAL ENGINEERING LETTERS, v.11, pp.183 - 195

ISSN
2093-9868
DOI
10.1007/s13534-021-00197-6
URI
http://hdl.handle.net/10203/287041
Appears in Collection
BiS-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0